J&J DRUG SALES UP 26% TO $829 MIL. IN QUARTER; U.S. DRUG REVENUES ARE $351 MIL.
Johnson & Johnson worldwide pharmaceutical sales increased 26% in the second quarter to $829 mil. and are ahead 23% through the first six months of 1990 at $1.6 bil. U.S. pharmaceuticals posted an "exceptionally strong" 31% increase to $351 mil., while overseas revenues advanced 22.6% to $478 mil. in the second quarter, J&J reported. Through six months, U.S. drug segment sales rose 22.7% to $666 mil. and international revenues totaled $961 mil., up 24%. The domestic increases were paced by Janssen USA, which had "significantly higher" revenues, J&J said, fueled by Hismanal, which posted "strong year-to-year comparisons," "strong" sales of Nizoral, Imodium, Janssen's anesthesiology product line and overseas introductions of Eprex (EPO). Quarterly corporate revenues jumped 18.2% to $2.8 bil. and are 17.1% higher for the year so far at $5.7 bil. Consolidated net income for the second quarter was $353 mil., up 18.9%. Year-to-date earnings, however, slipped 2.8% to $597 mil. due to a first quarter one-time charge "for the permanent impairment of certain assets and operations in Latin America."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth